-
公开(公告)号：US09765108B2
公开(公告)日：2017-09-19
申请号：US14441517
申请日：2013-11-08
摘要： The present invention relates to polymorphic forms of 5-Azacytidine and the process for preparation thereof. The present invention further relates to Crystalline 5-azacytidine 5 designated as Form-SA-1 characterized by an X-ray powder diffraction pattern having at least four characteristic diffraction angle peaks at about 12.00, 12.60, 13.90, 15.15 and 31.40±0.20 2θ°, which is useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of myelodysplastic syndrome.
-
公开(公告)号：US20150284421A1
公开(公告)日：2015-10-08
申请号：US14441517
申请日：2013-11-08
IPC分类号： C07H19/12
摘要： The present invention relates to lyophilized formulations comprising crystalline 5-azacytidine and process for preparing lyophilized formulations comprising crystalline 5-azacytidine.
摘要翻译： 本发明涉及包含结晶5-氮杂胞苷的冻干制剂和用于制备包含结晶5-氮杂胞苷的冻干制剂的方法。
-
公开(公告)号：US20140336246A1
公开(公告)日：2014-11-13
申请号：US14349332
申请日：2012-12-26
发明人： Vimal Kumar Shrawat , Prashant Purohit , Rafiuddin Dr , Vinod Kumar Singh , Akshaykant Chaturvedi
IPC分类号： C07D305/14
CPC分类号： C07D305/14 , C07D413/12
摘要： The present invention provides a non-solvated amorphous form of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof.The present application also provides a non-solvated amorphous form of (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG. 1, and IR spectrum as per FIG. 3 and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.
摘要翻译： 本发明提供一种非溶剂化无定形形式的（2α，5α，b，10α，17α）-4-乙酸基 - 13 - （{（2R，3S）-3 [（叔丁氧基羰基）氨基] -2-羟基-3-苯基丙酰基}氧基）-1-羟基-7,10-二甲氧基-9-氧代-5,20-环氧基十二烷-1-烯-2-基苯甲酸酯或卡巴他赛（I），以及制备方法 其中。 本申请还提供非溶剂化无定形形式的（2α，5β，7α，b，10α，13α）-4-乙酸基 - 13 - （{（2R，3S）-3 [（叔丁氧基羰基）氨基 ] -2-羟基-3-苯基丙酰基}氧基）-1-羟基-7,10-二甲氧基-9-氧代-5,20-环氧塔塔-1-烯-2-基苯甲酸酯或具有XRPD图案的卡巴他赛（I） 根据图 1和IR光谱如图1所示。 并且可用作其包含其的药物组合物中的活性药物并具有抗癌活性。
-
公开(公告)号：US09708352B2
公开(公告)日：2017-07-18
申请号：US15108790
申请日：2015-01-01
CPC分类号： C07F9/202 , C07B2200/13 , C07F9/17
摘要： The present invention relates to a process for preparation of Echothiophate Iodide (I). Echothiophate Iodide (I) obtained by the process of the present invention is obtained as new crystalline form designated as Form-SET. The process for preparation of Echothiophate Iodide (I) according to present invention is an ecofriendly process that avoids the use of hazardous solvent systems and provides Echothiophate Iodide (I) of high purity. Pharmaceutical composition of the said crystalline Form-SET of Echothiophate Iodide (I) of high purity is useful in the treatment of ocular disorders like Glaucoma.
-
公开(公告)号：US09732030B2
公开(公告)日：2017-08-15
申请号：US14759224
申请日：2014-01-11
IPC分类号： C07C213/00 , C07C231/12
CPC分类号： C07C213/00 , C07B2200/13 , C07C231/12 , C07C215/28 , C07C233/31 , C07C233/18
摘要： The present invention provides process for preparation of Fingolimod hydrochloride (I). Fingolimod hydrochloride (I) as Form-β obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
